Sonus completes EchoGen filing
The Food and Drug Administration has notified ultrasound contrast agent developer Sonus Pharmaceuticals of Bothell, WA, that its amended new drug application for EchoGen is complete. The news came after Sonus provided the FDA with the information the
The Food and Drug Administration has notified ultrasound contrast agent developer Sonus Pharmaceuticals of Bothell, WA, that its amended new drug application for EchoGen is complete. The news came after Sonus provided the FDA with the information the agency had asked for last month regarding EchoGens NDA amendment filing (SCAN 10/28/98).
Sonus executives had stated that the FDAs request for more information might delay EchoGens road to approval, but it appears that any delay will be insignificant in light of the FDAs acceptance of the filing. The FDA now has up to six months, beginning Oct. 19, to review EchoGens NDA.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
